{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:59:15Z","timestamp":1787237955760,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40262-025-01535-y","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:15:42Z","timestamp":1754064942000},"page":"1531-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct00364182","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01335061","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00037557","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00093171","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00093210","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03861273","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03307980","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02484092","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8742","authenticated-orcid":false,"given":"Jessica","family":"Wojciechowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5617-5495","authenticated-orcid":false,"given":"Puneet","family":"Gaitonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-5805","authenticated-orcid":false,"given":"Jim H.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patanjali","family":"Ravva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"1","key":"1535_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47. https:\/\/doi.org\/10.1111\/j.1365-2516.2012.02909.x.","journal-title":"Haemophilia"},{"issue":"3","key":"1535_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13998","volume":"26","author":"JM Soucie","year":"2020","unstructured":"Soucie JM, Miller CH, Dupervil B, et al. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia. 2020;26(3):487\u201393. https:\/\/doi.org\/10.1111\/hae.13998.","journal-title":"Haemophilia"},{"key":"1535_CR3","unstructured":"World Federation of Hemophilia. World Federation of Hemophilia Report on the annual global survey 2022. 2023 (last update Oct 2023). https:\/\/www1.wfh.org\/publications\/files\/pdf-2399.pdf. Accessed 04 Oct 2024."},{"issue":"4","key":"1535_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5435\/00124635-200407000-00004","volume":"12","author":"JV Luck Jr","year":"2004","unstructured":"Luck JV Jr, Silva M, Rodriguez-Merchan CE, et al. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12(4):234\u20135. https:\/\/doi.org\/10.5435\/00124635-200407000-00004.","journal-title":"J Am Acad Orthop Surg"},{"issue":"3","key":"1535_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1055\/a-1175-6530","volume":"40","author":"A Trinchero","year":"2020","unstructured":"Trinchero A, Sholzberg M, Matino D. The evolution of hemophilia care: clinical and laboratory advances, opportunities, and challenges. Hamostaseologie. 2020;40(3):311\u201321. https:\/\/doi.org\/10.1055\/a-1175-6530.","journal-title":"Hamostaseologie"},{"issue":"2","key":"1535_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1055\/s-0041-1722862","volume":"47","author":"VR Arruda","year":"2021","unstructured":"Arruda VR, Weber J, Samelson-Jones BJ. Gene therapy for inherited bleeding disorders. Semin Thromb Hemost. 2021;47(2):161\u201373. https:\/\/doi.org\/10.1055\/s-0041-1722862.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"1535_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/hematology.2022000388","volume":"2022","author":"AC Nathwani","year":"2022","unstructured":"Nathwani AC. Gene therapy for hemophilia. Hematol Am Soc Hematol Educ Program. 2022;2022(1):569\u201378. https:\/\/doi.org\/10.1182\/hematology.2022000388.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"Suppl 1","key":"1535_CR8","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1111\/jth.12926","volume":"13","author":"T Ohmori","year":"2015","unstructured":"Ohmori T, Mizukami H, Ozawa K, et al. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost. 2015;13(Suppl 1):S133\u201342. https:\/\/doi.org\/10.1111\/jth.12926.","journal-title":"J Thromb Haemost"},{"issue":"23","key":"1535_CR9","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708538.","journal-title":"N Engl J Med"},{"key":"1535_CR10","unstructured":"Pfizer. BEQVEZ (fidanacogene elaparvovec-dzkt) prescribing information. 2024 (last update April 2024). https:\/\/www.fda.gov\/media\/178140\/download?attachment. Accessed 04 Oct 2024."},{"key":"1535_CR11","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of positive opinion for Durveqtix (fidanacogene elaparvovec). 2024 (last update 08 Jan 2024). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/durveqtix. accessed 04 Oct 2024."},{"key":"1535_CR12","unstructured":"Pfizer Canada. Health Canada approves Pfizer Canada\u2019s gene therapy in hemophilia B [media release]. 2024 (last update 03 Jan 2024). https:\/\/www.pfizer.ca\/en\/media-centre\/health-canada-approves-pfizer-canadas-gene-therapy-in-hemophilia-b. Accessed 04 Oct 2024."},{"issue":"12","key":"1535_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","volume":"391","author":"A Cuker","year":"2024","unstructured":"Cuker A, Kavakli K, Frenzel L, et al. Gene therapy with fidanacogene elaparvovec in adults with hemophilia B. N Engl J Med. 2024;391(12):1108\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2302982.","journal-title":"N Engl J Med"},{"key":"1535_CR14","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1182\/blood-2021-150541","volume":"138","author":"BJ Samelson-Jones","year":"2021","unstructured":"Samelson-Jones BJ, Sullivan SK, Rasko JEJ, et al. Follow-up of more than 5 years in a cohort of patients with hemophilia b treated with fidanacogene elaparvovec adeno-associated virus gene therapy. Blood. 2021;138:3975. https:\/\/doi.org\/10.1182\/blood-2021-150541.","journal-title":"Blood"},{"issue":"5","key":"1535_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/hae.12188","volume":"19","author":"S Bj\u00f6rkman","year":"2013","unstructured":"Bj\u00f6rkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia. 2013;19(5):753\u20137. https:\/\/doi.org\/10.1111\/hae.12188.","journal-title":"Haemophilia"},{"issue":"6","key":"1535_CR16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00228-012-1211-z","volume":"68","author":"S Bj\u00f6rkman","year":"2012","unstructured":"Bj\u00f6rkman S, Ahl\u00e9n V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol. 2012;68(6):969\u201377. https:\/\/doi.org\/10.1007\/s00228-012-1211-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1535_CR17","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/jth.13271","volume":"14","author":"A Brekkan","year":"2016","unstructured":"Brekkan A, Berntorp E, Jensen K, et al. Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. J Thromb Haemost. 2016;14(4):724\u201332. https:\/\/doi.org\/10.1111\/jth.13271.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"1535_CR18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jth.12000","volume":"10","author":"PW Collins","year":"2012","unstructured":"Collins PW, M\u00f8ss J, Knobe K, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost. 2012;10(11):2305\u201312. https:\/\/doi.org\/10.1111\/jth.12000.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1535_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40262-013-0129-7","volume":"53","author":"L Diao","year":"2014","unstructured":"Diao L, Li S, Ludden T, et al. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet. 2014;53(5):467\u201377. https:\/\/doi.org\/10.1007\/s40262-013-0129-7.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1535_CR20","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1111\/hae.12969","volume":"22","author":"A Suzuki","year":"2016","unstructured":"Suzuki A, Tomono Y, Korth-Bradley JM. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B. Haemophilia. 2016;22(5):e359\u201366. https:\/\/doi.org\/10.1111\/hae.12969.","journal-title":"Haemophilia"},{"issue":"11","key":"1535_CR21","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/jth.13444","volume":"14","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Roberts J, Bensen-Kennedy D, et al. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. J Thromb Haemost. 2016;14(11):2132\u201340. https:\/\/doi.org\/10.1111\/jth.13444.","journal-title":"J Thromb Haemost"},{"key":"1535_CR22","unstructured":"Pfizer: BeneFIX (coagulation factor IX [recombinant]) prescribing information. 2021 (last update April 2021). https:\/\/www.fda.gov\/media\/73556\/download?attachment. Accessed 04 Oct 2024."},{"key":"1535_CR23","volume-title":"NONMEM user\u2019s guides (1989\u20132017)","author":"S Beal","year":"2017","unstructured":"Beal S, Sheiner LB, Boeckmann A, et al. NONMEM user\u2019s guides (1989\u20132017). Gaithersburg: ICON Development Solutions; 2017."},{"key":"1535_CR24","unstructured":"R Core Team. R: a language and environment for statistical computing. 2019. https:\/\/www.r-project.org\/. Accessed 04 Oct 2024."},{"issue":"12","key":"1535_CR25","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1096\/fasebj.3.12.2676679","volume":"3","author":"JL Hargrove","year":"1989","unstructured":"Hargrove JL, Schmidt FH. The role of mRNA and protein stability in gene expression. FASEB J. 1989;3(12):2360\u201370. https:\/\/doi.org\/10.1096\/fasebj.3.12.2676679.","journal-title":"FASEB J"},{"issue":"1","key":"1535_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1021\/acs.molpharmaceut.2c00555","volume":"20","author":"P Zou","year":"2023","unstructured":"Zou P. First-in-patient dose prediction for adeno-associated virus-mediated hemophilia gene therapy using allometric scaling. Mol Pharm. 2023;20(1):758\u201366. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00555.","journal-title":"Mol Pharm"},{"issue":"9","key":"1535_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1(9): e6. https:\/\/doi.org\/10.1038\/psp.2012.4.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"1535_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"AG Dosne","year":"2017","unstructured":"Dosne AG, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44(6):509\u201320. https:\/\/doi.org\/10.1007\/s10928-017-9542-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1535_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"issue":"4","key":"1535_CR30","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri M, Levy DI, Schulz M, et al. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30(4):1364\u201380. https:\/\/doi.org\/10.1016\/j.ymthe.2022.03.004.","journal-title":"Mol Ther"},{"issue":"3","key":"1535_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","volume":"31","author":"M Schulz","year":"2023","unstructured":"Schulz M, Levy DI, Petropoulos CJ, et al. Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy. Mol Ther. 2023;31(3):616\u201330. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.010.","journal-title":"Mol Ther"},{"issue":"Pt 9","key":"1535_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1242\/jeb.01589","volume":"208","author":"GB West","year":"2005","unstructured":"West GB, Brown JH. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol. 2005;208(Pt 9):1575\u201392. https:\/\/doi.org\/10.1242\/jeb.01589.","journal-title":"J Exp Biol"},{"issue":"14","key":"1535_CR33","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.3748\/wjg.v12.i4.2217","volume":"12","author":"SC Chan","year":"2006","unstructured":"Chan SC, Liu CL, Lo CM, et al. Estimating liver weight of adults by body weight and gender. World J Gastroenterol. 2006;12(14):2217\u201322. https:\/\/doi.org\/10.3748\/wjg.v12.i4.2217.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1535_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/03007995.2022.2133492","volume":"39","author":"J Shah","year":"2023","unstructured":"Shah J, Kim H, Sivamurthy K, et al. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Med Res Opin. 2023;39(2):227\u201337. https:\/\/doi.org\/10.1080\/03007995.2022.2133492.","journal-title":"Curr Med Res Opin"},{"key":"1535_CR35","unstructured":"CSL Behring LLC. HEMGENIX (etranacogene dezaparvovec-drlb) prescribing information. 2022 (last update November 2022). https:\/\/www.fda.gov\/media\/163467\/download?attachment. Accessed 04 Oct 2024."},{"issue":"21","key":"1535_CR36","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","volume":"3","author":"A Von Drygalski","year":"2019","unstructured":"Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21):3241\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2019000811.","journal-title":"Blood Adv"},{"issue":"Suppl 2","key":"1535_CR37","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1002\/rth2.12589","volume":"5","author":"E Gomez","year":"2021","unstructured":"Gomez E, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AAV5-Padua hFIX Variant, AMT-061), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B: 2.5 Year data from a phase 2b trial [abstract]. Res Pract Thromb Haemost. 2021;5(Suppl 2):e12589. https:\/\/doi.org\/10.1002\/rth2.12589.","journal-title":"Res Pract Thromb Haemost."},{"issue":"Suppl 1","key":"1535_CR38","doi-asserted-by":"publisher","first-page":"PO143","DOI":"10.1111\/hae.14479","volume":"28","author":"W Miesbach","year":"2022","unstructured":"Miesbach W, Leebeek F, Recht M, et al. Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B. Haemophilia. 2022;28(Suppl 1):PO143. https:\/\/doi.org\/10.1111\/hae.14479.","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"1535_CR39","doi-asserted-by":"publisher","first-page":"PO182","DOI":"10.1111\/hae.14919","volume":"30","author":"J Wojciechowski","year":"2024","unstructured":"Wojciechowski J, Gaitonde P, Wilcox L. Simulation of extended half-life replacement fix therapy dosing to achieve comparable fix activity to that of fidanacogene elaparvovec gene therapy in haemophilia B patients [abstract]. Haemophilia. 2024;30(Suppl 1):PO182. https:\/\/doi.org\/10.1111\/hae.14919.","journal-title":"Haemophilia"},{"issue":"10","key":"1535_CR40","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1055\/s-0044-1787734","volume":"124","author":"DD Pittman","year":"2024","unstructured":"Pittman DD, Carrieri C, Soares H, et al. Field study and correlative studies of factor IX variant FIX-R338L in Participants treated with fidanacogene elaparvovec. Thromb Haemost. 2024;124(10):912\u201321. https:\/\/doi.org\/10.1055\/s-0044-1787734.","journal-title":"Thromb Haemost"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01535-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:48:58Z","timestamp":1759146538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01535-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"21 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jessica Wojciechowski was employed at Pfizer at the time of this study. Puneet Gaitonde, Jim H. Hughes, and Patanjali Ravva are employees of and shareholders in Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All clinical trials were approved by the appropriate local Independent Ethics Committee (IEC) or Institutional Review Board (IRB) and informed consent was obtained from all participants. Trials were carried out in concordance with ICH Guidelines for Good Clinical Practice. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\u00a0\n                      \n                      for more information.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The code for the final NONMEM\n                      \u00ae\n                      model is available in the electronic supplementary material.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"J.W. and P.G. conceived and designed the research; J.W. and J.H.H performed the data analysis and quality review; and J.W., P.G., and P.R. reviewed and interpreted the results. All authors critically made a substantial contribution in writing the paper, reviewed the manuscript, and approved the final version for submission.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Consent was obtained from participants in all trials.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Written informed consent was obtained for all participants before conducting any study procedures.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}